Amer Assal, MD

Photos

520 E 70th St Fl 3
New York, NY 10021
Amer Assal MD is a board certified medical oncologist and hematologist who specializes in the use of autologous and allogeneic bone marrow stem cell transplantation for the treatment of multiple myeloma, leukemia, lymphoma, myelodysplastic syndromes and other bone marrow disorders. Dr. Assal completed his medical education and internal medicine training at NYU School of Medicine. He was also a hospitalist in the department of medicine at Memorial Sloan Kettering Cancer Center caring for patients with a variety of cancer diagnoses, including stem cell transplant patients. Dr. Assal completed a fellowship in hematology and medical oncology at Albert Einstein College of Medicine where he also served as chief fellow. He finally completed a fellowship in blood and marrow stem cell transplantation at Memorial Sloan Kettering Cancer Center. His research interests center around improving outcomes of stem cell transplantation and the diseases it is used to treat. He has a particular interest in immunotherapy and studying ways to harness the immune system to attack tumor cells, while at the same time decreasing the risk of graft versus host disease. He is also interested in studying therapeutic interventions to prevent and treat relapse of disease after stem cell transplantation. He has presented his research at several national conferences and was awarded an American Society of Hematology Abstract Achievement award for his research.
Owner verified
See a problem?

You might also like

Michal Bar-Natan, M.D.
Internal medicine practitioners

Michal Bar-Natan, M.D.

Michal Bar-Natan, MD, is Interim Assistant Professor of Medicine and a member of the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York City. Dr. Bar-Natan graduated cum laude from the Sackler School of Medicine. She completed her Internal Medicine Residency at Sheba Medical Center and her Fellowship in Hematology and Medical Oncology at NYU Langone Health. In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women’s Hospital (Harvard Medical School) with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms (MPNs) and leukemias.Prior to this position Dr. Bar-Natan served as Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai, an Attending Physician with the Center of Excellence for Blood Cancers and Myeloid Disorders, and as the leader of the Acute Lymphoblastic Leukemia program at the Mt. Sinai Tisch Cancer Institute. Dr. Bar-Natan’s focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials for patients with these conditions. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as the PI and co-investigator on many clinical trials for acute leukemias and myeloproliferative neoplasms.
United StatesNew YorkNew YorkAmer Assal, MD

Yext